Carole Ben Maimon Larimar Therapeutics, Inc. (LRMR) insider trading activity

Carole Ben Maimon is President and CEO of Larimar Therapeutics, Inc.. Currently has a direct ownership of 387,208 shares of LRMR, which is worth approximately $1.32 Million. The most recent transaction as insider was on Jan 22, 2025, when has been sold 91,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 387K

16.29% 3M change

16.29% 12M change

Total Value Held $1.32 Million

CAROLE BEN-MAIMON Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 22 2025	BUY Grant, award, or other acquisition	-	91,000 Added 19.03%	387,208 Common Stock
Jan 17 2024	BUY Grant, award, or other acquisition	-	66,125 Added 16.57%	332,954 Common Stock
May 17 2023	BUY Open market or private purchase	$18,500 $3.7 p/Share	5,000 Added 1.84%	266,829 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	-	205,000 Added 43.91%	261,829 Common Stock
Sep 16 2022	BUY Open market or private purchase	$100,000 $3.15 p/Share	31,746 Added 35.84%	56,829 Common Stock

Also insider at

TLGTQ

Teligent, Inc. Healthcare

Director